Hanne Leth Hillman

Président chez The Danish Investor Relations Society

59 ans

Health Technology

Transportation

Finance

Postes actifs de Hanne Leth Hillman

Sociétés	Poste	Début	Fin
The Danish Investor Relations Society	Président	-	-
The Danish Investor Relations Society	Directeur/Membre du Conseil	-	-
Nanovi Radiotherapy A/S Nanovi Radiotherapy A/S Pharmaceuticals: MajorHealth Technology Nanovi Radiotherapy A/S provides radiotherapy related products for the treatment of cancer. Its product BioXmark is a liquid ready-to-insert fiducial marker, which once inserted into soft tissue forms a semi-solid gel. The firm's platform provides an opportunity to encapsulate chemotherapeutics within the gel. The company was founded by Thomas Lars Andresen and Morten Albrechtsen in 2012 and is headquartered in Kongens Lyngby, Denmark.	Directeur Financier/CFO	01/05/2017	-

Sociétés	Poste	Début	Fin
BRAIN+ A/S	Directeur/Membre du Conseil	01/05/2021	01/01/2024
	Directeur Financier/CFO	01/09/2022	01/01/2024
	Independent Dir/Board Member	01/05/2021	01/09/2022
ZEALAND PHARMA A/S	Investor Relations Contact	01/01/2011	01/10/2016
ZEALAND PHARMA A/S	Public Communications Contact	01/01/2011	01/10/2016
Gudme Raaschou Bank A/S	Analyst-Equity	05/11/2004	05/11/2004
NTG NORDIC TRANSPORT GROUP A/S	Investor Relations Contact	-	-
NTG NORDIC TRANSPORT GROUP A/S	Public Communications Contact	28/08/2009	-

University of Aarhus

Masters Business Admin

Internationale

Danemark

Opérationnelle

Investor Relations Contact	2
Public Communications Contact	2
Director/Board Member	2

Sectorielle

Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Sociétés cotées	3
NTG NORDIC TRANSPORT GROUP A/S	Transportation
ZEALAND PHARMA A/S	Health Technology
BRAIN+ A/S	Technology Services

Entreprise privées	3
Gudme Raaschou Bank A/S	Finance
The Danish Investor Relations Society
Nanovi Radiotherapy A/S Nanovi Radiotherapy A/S Pharmaceuticals: MajorHealth Technology Nanovi Radiotherapy A/S provides radiotherapy related products for the treatment of cancer. Its product BioXmark is a liquid ready-to-insert fiducial marker, which once inserted into soft tissue forms a semi-solid gel. The firm's platform provides an opportunity to encapsulate chemotherapeutics within the gel. The company was founded by Thomas Lars Andresen and Morten Albrechtsen in 2012 and is headquartered in Kongens Lyngby, Denmark.	Health Technology